Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Avanos Medical, Inc. (NYSE: AVNS), a medical technology company headquartered in Alpharetta, Georgia. Through these filings, investors can review how Avanos reports its financial performance, strategic actions and governance matters related to its Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments.
Avanos uses current reports on Form 8-K to disclose material events. These include earnings releases that present quarterly and year-to-date results, segment net sales and operating income, and non-GAAP measures such as adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted EBITDA and free cash flow. The company explains in these filings which items are excluded from non-GAAP measures, such as acquisition and integration charges, restructuring and transformation expenses, EU Medical Device Regulation compliance costs, amortization of acquisition-related intangibles, impairments, certain tax effects and currency impacts.
Form 8-K filings also document strategic portfolio moves and organizational changes. Avanos has furnished press releases describing the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, the agreement for WRS Group to acquire its US Game Ready orthopedic rental business and the acquisition of Nexus Medical, LLC. Other 8-K items cover executive appointments, board changes and an organizational restructuring that eliminated certain senior roles, along with details of severance and equity treatment under the company’s established plans.
Stock Titan enhances these regulatory disclosures with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of earnings releases, transaction announcements and governance updates. Real-time ingestion of EDGAR data means new Avanos Forms 8-K and other SEC documents appear promptly, while AI-generated overviews and tagging make it easier to locate information on segment performance, non-GAAP reconciliations and executive compensation arrangements.